THE WOODLANDS VGXI Inc., a Woodlands-based manufacturer of plasmid DNA used in vaccine and gene therapy clinical trials announced an expansion that will double its capacity and likely create jobs, according to VGXI Inc. Business Development Manager Christy Franco.

The expansion will add 3,000 square feet to the building, located at 2700 Research Forest Drive, and will include a small-scale cGMP (compliant with the U.S. Food and Drug Administrations current Good Manufacturing Practice regulations) production plant.

The expansion is in response to recent growth in the market for DNA-based pharmaceuticals.

Weve been seeing it coming, Franco said of the need to expand facilities. Clients need quality DNA for clinical trials.

This is an exciting time for the field of gene therapy and DNA vaccines, Franco state d in a press release. As these technologies mature, more and more companies are moving their products into clinical trials and closer to regulatory approval.

Franco said VGXI is contracted at capacity and the expansion will allow the company to perform multiple client campaigns simultaneously.

VGXI Inc., which employees 40-50 people in The Woodlands, has manufactured plasmid products for clinical trials in the U.S., EU, Asia and Australia over the past 15 years using a patented manufacturing process.

VGXI is a wholly owned subsidiary contract manufacturing organization of GeneOne Life Science Inc. and received the Vaccine Industry Excellence Award for best CMO in 2013 and 2014.

Continue reading here:
Woodlands-based DNA manufacturer expands facilities

Comments are closed.